The FDA’s approval of ipilimumab (a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTL-4) in melanoma) and sipuleucel-T (a personalized immunotherapy treatment for prostate cancers) encourages further immunotherapy research in glioma. Here, CTLA4 is linked to glioma.